| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ATRA | CTRPv2 | pan-cancer | AAC | 0.34 | 2e-23 |
| mRNA | tretinoin:carboplatin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.3 | 8e-18 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.27 | 5e-14 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.26 | 4e-13 |
| mRNA | Sunitinib | CTRPv2 | pan-cancer | AAC | 0.25 | 5e-13 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | 0.26 | 5e-12 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.23 | 5e-12 |
| mRNA | staurosporine | CTRPv2 | pan-cancer | AAC | 0.43 | 5e-10 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | 0.22 | 6e-10 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | 0.22 | 6e-10 |